Sex-Gender Differences Are Completely Neglected in Treatments for Neuropathic Pain

Francesco Salis

Co-prime

Member of the Collaboration Group

;Salvatore Sardo

Co-prime

Member of the Collaboration Group

;Gabriele Finco

Member of the Collaboration Group

;Gian Luigi Gessa

Member of the Collaboration Group

;Flavia Franconi

Member of the Collaboration Group

;Roberta Agabio

Last

Member of the Collaboration Group

2024-01-01

---

Abstract

As sex-gender differences have been described in the responses of patients to certain medications, we hypothesized that the responses to medications recommended for neuropathic pain may differ between men and women. We conducted a literature review to identify articles reporting potential sex-gender differences in the efficacy and safety of these medications. Only a limited number of studies investigated potential sex-gender differences. Our results show that women seem to achieve higher blood concentrations than men during treatment with amitriptyline, nortriptyline, duloxetine, venlafaxine, and pregabalin. Compared to men, higher rates of women develop side effects during treatment with gabapentin, lidocaine, and tramadol. Globally, the sexgender differences would suggest initially administering smaller doses of these medications to women with neuropathic pain compared to those administered to men. However, most of these differences have been revealed by studies focused on the treatment of other diseases (e.g., depression). Studies focused on neuropathic pain have overlooked potential sex-gender differences in patient responses to medications. Despite the fact that up to 60% of patients with neuropathic pain fail to achieve an adequate response to medications, the potential role of sex-gender differences in the efficacy and safety of pharmacotherapy has not adequately been investigated. Targeted studies should be implemented to facilitate personalized treatments for neuropathic pain.